Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This study will be conducted as a Phase Ib, open-label, non-randomized, single-institution
study to evaluate the safety and tolerability of carfilzomib in combination with bendamustine
and rituximab in patients with relapsed or refractory NHL and to determine the recommended
phase II dose and preliminary efficacy of this combination. The study will have two phases: a
dose-escalation phase to determine the maximal tolerated dose of carfilzomib in this
combination where participants will be monitored for toxicity, tolerability and response and
a dose-expansion phase that will determine the preliminary efficacy in patients with Mantle
cell lymphoma or any other disease subtype in which there is a preliminary efficacy signal
observed.